MEDICAL POLICY STATEMENT
Arkansas PASSE

Policy Name & Number	Date Effective
Epidural Steroid Injections-AR PASSE-MM-1504	11/01/2026
Policy Type	
MEDICAL	

Medical Policy Statements are developed from a review of the available evidence-based, clinical information based on and supported by clinical guidelines from medical specialties, peer-reviewed medical and scientific studies, nationally recognized utilization and technology assessment guidelines, and other medical management industry standards to aid in determining the medical necessity of a service. Medically necessary services are defined in the plan-specific Evidence of Coverage, Member Handbooks, Provider Manuals, Medical Policy Statements, and/or other plan policies and procedures.

Medical Policy Statements do not guarantee an authorization or payment of services. Please refer to the plan contract (e.g., Evidence of Coverage, Member Handbook) for the service(s) referenced in the Medical Policy Statement. Except as otherwise required by law, if there is a conflict between the Medical Policy Statement and the plan contract and/or provider agreement, then the plan contract and/or provider agreement will be the controlling document. Reasonable discretion may be used in interpreting and applying this Policy Statement to services provided in a particular case, and the policy may be modified at any time. Medical Policy Statements may be superseded by federal and state laws and regulations, as applicable. In the case of a discrepancy between the Policy Statement's effective date and any applicable legal or regulatory requirement, the law or regulation will govern.

Coverage for mental health and substance use disorder (MH/SUD) benefits are provided at the same level as coverage for medical and surgical (M/S) benefits, as required by the Mental Health Parity and Addiction Equity Act (MHPAEA). MH/SUD benefits are not subject to limits or requirements that are more restrictive than those that apply to M/S benefits.

Table of Contents

A. Subject 2
B. Background 2
C. Definitions 2
D. Policy 3
E. Conditions of Coverage 5
F. Related Policies/Rules 5
G. Review/Revision History 6
H. References 6

A. Subject

Epidural Steroid Injections

B. Background

Over 80% of adults experience back pain during their lifetime. Long-term outcomes are largely favorable for most patients, but a small percentage of patients' symptoms are persistent. Persistent pain is categorized as subacute when lasting between 4 and 12 weeks and chronic when persisting for at least 3 months.

Comprehensive pain management care plans are most effective in managing a patient's chronic pain. These plans focus on a person-centered approach and incorporate conservative treatment with other modalities. These multidisciplinary treatments include promoting patient self-management and aim to reduce the impact of pain on a patient's daily life, even if the pain cannot be relieved completely. In addition to conservative therapy, additional treatment options may include nonpharmacologic or pharmacologic treatments, nonsurgical interventions, and surgical interventions. Interventional procedures for the management of pain unresponsive to conservative treatment should be provided only by providers qualified to deliver these health services.

Epidural steroid injections (ESIs) are a nonsurgical, minimally invasive intervention for chronic back pain. ESIs may be administered through the translaminar approach (via the interlaminar space in the spine), the transforaminal approach (through the neuroforamen dorsal to the nerve root), or the caudal approach (through the sacral hiatus at the sacral canal). There is conflicting evidence on the efficacy of ESIs and a lack of consensus on frequency and number of epidural steroid injections from professional organizations. However, clinical experience suggests that some patients obtain more significant relief, making it reasonable to offer a trial of steroid injections when conservative management has failed.

Imaging studies of the symptomatic region may be performed to evaluate suspected specific causes of spinal pain (eg, herniated disc, spinal stenosis, degenerative vertebral disease, rule out fracture or tumor). However, evidence does not support the routine use of imaging or other diagnostic tests in patients with nonspecific back pain. Diagnostic imaging and testing are only recommended when severe or progressive neurologic deficits are present or when serious underlying conditions are suspected on the basis of history and physical examination.

This policy focuses on ESIs as an intervention for chronic back pain management and does not apply to labor and delivery or surgical anesthesia.

C. Definitions

- **Conservative Therapy** – A multimodal plan of care including both active and inactive conservative therapies.
  - **Active Conservative Therapies** – Actions or activities that strengthen muscle groups and target key spinal structures, including physical therapy, occupational

therapy, a physician supervised home exercise program (HEP), and/or chiropractic care.
    - **HEP** – A prescribed plan that includes specific goals, frequency, and expected duration, along with a clearly defined timeframe for reassessment (eg, 6-12 weeks). Ongoing continuation must be supported by documented clinical progress Patient inconvenience or noncompliance without explanation does not constitute an inability to complete.
  - **Inactive Conservative Therapies** – Passive activities by the patient that aid in treating symptoms associated with pain, including rest, ice, heat, medical devices, Transcutaneous Electrical Nerve Stimulator (TENS) use, and/or pharmacotherapy (prescription or over the counter [eg, non-steroidal anti-inflammatory drugs, acetaminophen]).
- **Epidural Steroid Injection** – Administration of steroids via a needle inserted in the epidural space of the spine. Injections are intended to cause a short-term reduction in pain in the affected region.

D. Policy

I. Initial (Diagnostic) Injection
CareSource considers an initial (diagnostic) epidural steroid injection (maximum of 2 injections) medically necessary for the management of subacute or chronic back pain when **ALL** the following clinical criteria are met:
   A. Pain is located in either the cervical, thoracic, or lumbar spine and is predominantly radiating or shooting in nature.
   B. Pain is causing moderate to severe functional impairment (at least a 6 on a scale of 0 to 10) as documented by provider.
   C. Signs or symptoms are consistent with radiculopathy, as indicated by at least 1 of the following:
      1. diminished or absent deep tendon reflexes
      2. paresthesia, numbness, sensory change, or weakness in dermatomal distribution
      3. positive femoral nerve stretch test
      4. positive Spurling's test
      5. positive straight leg raise test
   D. Conservative therapy has failed to alleviate symptoms, as evidenced by **ALL** the following:
      1. documentation in the medical record of at least 4 weeks of active conservative therapy (see definition above) within the past 6 months OR inability to complete active conservative therapy due to contraindication, increased pain, or intolerance
      2. documentation in the medical record of at least 4 weeks of inactive conservative therapy (see definition above) within the past 6 months
   E. Imaging (eg, x-ray, CT, MRI), if performed, demonstrates a spinal abnormality correlating with clinical symptoms and that there are no conditions present that would preclude the safety of the performance of the procedure.

II. Subsequent (Therapeutic) Injections
CareSource considers therapeutic epidural steroid injections medically necessary when **ALL** the following criteria are met:
A. The diagnostic or last therapeutic injection for current episode of pain provided significant functional pain relief of at least 50% as measured by a significant decrease in pain level, decrease in pain medications, and/or increase in physical function.
B. The member clinically continues to have ongoing pain or documented functional impairment (at least a 6 on a scale of 0 to 10).
C. At least 3 weeks have passed since the prior injection in order to reach pharmacodynamic effect.
D. No more than 3 procedures in a 12-week period of time per region are considered medically necessary.
E. The patient continues to engage in conservative therapy (see definition above).

III. Limitations and Exclusions
A. The maximum number of all epidural injections a member can receive in 12 months is 6, regardless of the number of levels involved.
B. For interlaminar or caudal epidural injections, no more than 1 epidural injection per treatment date should be performed.
C. For transforaminal epidurals or selective nerve root blocks (SNRBs), no more than 2 vertebral levels per treatment date, whether unilateral or bilateral, should be performed.
D. Real-time image guidance and any injection of contrast are inclusive components of epidural injections and are not compensated for separately or unbundled for coverage.
E. Conscious sedation, if required for co-morbidities or member/physician preference, may be provided without a medical necessity review but services will be considered part of the procedure and are not eligible for additional reimbursement if administered by a second provider.
F. Monitored anesthesia is considered not medically necessary.
G. Nerve blocks used as part of a surgical procedure or other medical procedure are not separately reimbursable but an inclusive component of that procedure. These injections will not be compensated separately or unbundled for coverage.
H. Members with indwelling implanted spinal cord stimulators or pain pumps must have a device interrogation report and an interpretation submitted with medical records and included in the prior authorization request for proposed interventional pain injections. If a device is not functioning properly, an escalation in pain may warrant evaluation and management of the implanted device.
I. Clinical evaluations and care of candidate members for epidural injections should also address, at the discretion of the physician and according to prevailing standards of medical care:
1. selected body imaging evaluations to evaluate the area of pain, particularly for acute pain, or to evaluate escalations in chronic baseline pain
2. appropriate imaging to rule out red flag conditions may be indicated if potential issues of trauma, osteomyelitis or malignancy, or other diagnoses are a concern

J. Contraindications include any of the following:
   1. pain related to cancer etiology
   2. local or systemic infection
   3. spinal trauma (eg, hematoma, hemorrhage, mass, ischemia)
   4. coagulopathy or high risk of bleeding (eg, advanced liver disease, advanced renal disease)

IV. Inconclusive or Non-Supportive Evidence
   A. Evidence reported in the medical literature is inconclusive as to the use of epidural injections for long term relief or treatment of chronic pain. Long-term continuation (epidural injections beyond 1 year) may be subject to medical necessity review.
   B. For both cervical and lumbar transforaminal (TF) ESIs, using particulate steroid is associated with a rare risk of catastrophic neurovascular complications such as stroke or death. Cervical transforaminal injections are risky because arterial supply may be densely concentrated in and around the intervertebral foramen. TF ESIs can be performed without contrast in patients with documented contraindication to its use. In these circumstances, particulate steroids are contraindicated and only the preservative free, particulate free steroids which are available should be used.
   C. Evidence supporting cervical TF ESIs for cervical radicular pain is limited. If performed, cervical TF ESIs should be performed by injecting contrast medium under real-time fluoroscopy and/or digital subtraction angiography (DSA) in a frontal plane, before injecting any substance potentially hazardous to the patient. Due to safety concerns identified in FDA warnings and subsequent expert consensus recommendations, particulate steroids should not be used for cervical TF injections.

E. Conditions of Coverage
NA

F. Related Policies/Rules
Facet Joint Interventions
Trigger Point Injections

G. Review/Revision History

	DATE	ACTION
Date Issued	05/10/2023	New policy, approved at Committee.
Date Revised	01/31/2024 01/15/2024 12/03/2025 08/12/2026	Annual review: updated references and formatting, approved at Committee. Review: removed US limitation, updated references, approved at Committee. Review: updated references, approved at Committee. Review: updated HEP definition, clarified injections as part of a surgical procedure, and changed 6 weeks of conservative therapy to 4. Approved at Committee
Date Effective	11/01/2026	
Date Archived		

H. References

1. Armon C, Narayanaswami P, et al. Epidural steroids for cervical and lumbar radicular pain and spinal stenosis systematic review summary: report of the AAN guidelines subcommittee. *Neurology.* 2025;104:e213361. doi:10.1212/WNL.0000000000213361
2. Chou R. Subacute and chronic low back pain: nonsurgical interventional treatment. UpToDate. Updated January 27, 2026. Accessed June 12, 2026. www.uptodate.com
3. Conger A, Cushman DM, Speckman RA, et al. The effectiveness of fluroscopically guided cervical transforaminal epidural steroid injection for the treatment of radicular pain; a systematic review and meta-analysis. *Pain Med.* 2020;21(1):41-54. doi:410.1093/pm/pnz127
4. Dydyk AM, Hu Y, Stretanski MF, et al. Cervical Epidural Injection. In: StatPearls [Internet]. Updated June 2, 2025. Accessed June 18, 2026. www.ncbi.nlm.nih.gov
5. Epidural Corticosteroid Injection: A-0225. MCG Health; 30th ed. Accessed June 19, 2026. www.careweb.careguidelines.com
6. Fromm MK, Liu SH, Carr C, et al. Factors associated with improved outcomes after lumbar transforaminal epidural steroid injections for radicular pain: a systematic review. *NASSJ*. 2025;21:100592. doi:10.1016/j.xnsj.2025.100592
7. Goel A, Singh S, Shukla NK, Yadav A. Efficacy of caudal epidural steroid injections in chronic low backache patients. *J Pharm Bioallied Sci.* 2023;15(Supple 1):S669-S672. doi:10.4103/jpbs.jpbs_89_23
8. Helm S, Harmon PC, Noe C, et al. Transforaminal epidural steroid injections: a systematic review and meta-analysis of efficacy and safety. *Pain Physician*. 2021;24:S209-S232. Accessed June 18, 2026. www.painphysicianjournal.com
9. Hsu P, Armon C, Levin K. Acute lumbosacral radiculopathy: Etiology, clinical features, and diagnosis. *UptoDate.* Updated July 1, 2025. Accessed June 18, 2026. www.uptodate.com
10. Manchikanti L, Knezevic NN, Navani A, et al. Epidural interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) comprehensive evidence-based guidelines. *Pain Physician.* 2021;24(S1): S27-S208. Reaffirmed (July 2025). Accessed June 18, 2026. www.painphysicianjournal.com

11. Oliveira CB, Maher CG, Ferreira ML, et al. Epidural corticosteroid injections for lumbosacral radicular pain. *Cochrane Database Syst Rev.* 2020;4(4):CD013577. doi:10.1002/14651858.CD013577
12. Sayed D, Grider J, Strand N, et al. The American Society of Pain and Neuroscience (ASPN) evidence-based clinical guidelines of interventional treatments for low back pain. *J Pain Res.* 2022;15:3729-3832. doi:10.2147/JPR.S386879
13. Tutton S, Riew KD, Fourney DR, et al. Safeguards to prevent neurologic complications after epidural steroid injections: consensus opinions from a multidisciplinary working group and national organizations *Anesthesiology*. 2015;122(5):974-984. doi:10.1097/ALN.0000000000000614
14. Verheijen EJA, Bonke CA, Amorij EMJ, Vleggeert-Lankamp CLA. Epidural steroid compared to placebo injection for sciatica: a systematic review and meta-analysis. *Euro Spine J*. 2021;30:3255-3264. doi:10.1007/s00586-021-06854-9
15. Yang S, Kim W, Kong HH, et al. Epidural steroid injection versus conservative treatment for patients with lumbosacral radicular pain: a meta-analysis of randomized controlled trials. *Med.* 2020;99(30):e21283. doi:10/1097/MD.0000000000021283